The appetite among #USbiotechs for #IPOs shows no signs of being satisfied, with three more companies – #ADARxPharma, #TRexBio, and #RetensionPharma – joining the lunch queue.
@pharmaphorum.bsky.social
Explore
@pharmaphorum.bsky.social
@pharmaphorum.bsky.socialThe appetite among #USbiotechs for #IPOs shows no signs of being satisfied, with three more companies – #ADARxPharma, #TRexBio, and #RetensionPharma – joining the lunch queue.